https://psychedelicbrief.com/https://psychedelicbrief.com/issues/16/https://psychedelicbrief.com/issues/16/AtaiBeckley told the SEC its BPL-003 Phase 3 had started. A quarter later there is no record of it on any registry, and the company no longer has to report.Tue, 29 Sep 2026 00:00:00 GMThttps://psychedelicbrief.com/issues/15/https://psychedelicbrief.com/issues/15/Lilly owes effort on TRD alone, and no holder can force it. A European Phase 3 can still trigger the first $1.00.Tue, 22 Sep 2026 00:00:00 GMThttps://psychedelicbrief.com/issues/14/https://psychedelicbrief.com/issues/14/Definium's Phase 3 ran on European patients and named one regulator. Lilly closed AtaiBeckley without an 8-K. Issue 4 scored.Tue, 15 Sep 2026 00:00:00 GMThttps://psychedelicbrief.com/issues/13/https://psychedelicbrief.com/issues/13/Denmark, Italy, the Netherlands. Three psychedelic trials authorised in August, invisible on the register everyone quotes.Tue, 08 Sep 2026 00:00:00 GMThttps://psychedelicbrief.com/issues/12/https://psychedelicbrief.com/issues/12/Four national approvals on one depression trial in a week. The register moved faster than our read of it.Tue, 01 Sep 2026 00:00:00 GMThttps://psychedelicbrief.com/issues/11/https://psychedelicbrief.com/issues/11/CTIS returns five authorised brenipatide trials under Lilly. The assets it paid $3.8 billion for appear in the same register under their own names: BPL-003 with one Phase 2b that ended last June, VLS-01 with nothing.Tue, 25 Aug 2026 00:00:00 GMThttps://psychedelicbrief.com/issues/10/https://psychedelicbrief.com/issues/10/Twenty-seven of the 28 compassionate use programmes on the German register are run by a pharmaceutical company. The psilocybin entry names a university institute and one psychiatrist.Tue, 18 Aug 2026 00:00:00 GMThttps://psychedelicbrief.com/issues/9/https://psychedelicbrief.com/issues/9/Britain's assessment machinery is built to start before a licence exists. It has nothing to start on. Twelve analysts took questions on Compass's last earnings call, and not one asked about Europe.Tue, 04 Aug 2026 00:00:00 GMThttps://psychedelicbrief.com/issues/8/https://psychedelicbrief.com/issues/8/Lilly is recruiting depression patients in four EU countries while its psychedelic deal names no European milestone at all. The difference is not Europe. It is what Europe costs to enter for a scheduled drug, and what nobody has yet asked it to pay.Tue, 28 Jul 2026 00:00:00 GMThttps://psychedelicbrief.com/issues/7/https://psychedelicbrief.com/issues/7/Eli Lilly bought AtaiBeckley for up to $3.8 billion and priced Europe at zero. Every regulatory milestone in the deal points at the FDA and the DEA. Not one points at the EMA.Tue, 21 Jul 2026 00:00:00 GMThttps://psychedelicbrief.com/issues/6/https://psychedelicbrief.com/issues/6/The durability data holding it up is thinner than the headline, and the trial that produced it had no placebo.Tue, 14 Jul 2026 00:00:00 GMThttps://psychedelicbrief.com/issues/5/https://psychedelicbrief.com/issues/5/The dividing line is whether patients have to quit their antidepressants first.Tue, 07 Jul 2026 00:00:00 GMThttps://psychedelicbrief.com/issues/4/https://psychedelicbrief.com/issues/4/It did it under the one design choice that sank EPIsoDE.Tue, 30 Jun 2026 00:00:00 GMThttps://psychedelicbrief.com/issues/3/https://psychedelicbrief.com/issues/3/Europe's most advanced psychedelic Phase 3 just got its hardest questionTue, 23 Jun 2026 00:00:00 GMThttps://psychedelicbrief.com/issues/2/https://psychedelicbrief.com/issues/2/The psilocybin trials, the H1 review left out. Two controlled European readouts complicate the real-world optimism. Here they are.Tue, 16 Jun 2026 00:00:00 GMThttps://psychedelicbrief.com/issues/1/https://psychedelicbrief.com/issues/1/Tue, 09 Jun 2026 00:00:00 GMT